Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective

Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavacchi, Daniele, Pellegrini, Elisa, Palmieri, Valeria Emma, Doni, Laura, Mela, Marinella Micol, Di Maida, Fabrizio, Amedei, Amedeo, Pillozzi, Serena, Carini, Marco, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369721/
https://www.ncbi.nlm.nih.gov/pubmed/32630154
http://dx.doi.org/10.3390/ijms21134691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369721/
https://www.ncbi.nlm.nih.gov/pubmed/32630154
http://dx.doi.org/10.3390/ijms21134691

Ejemplares similares